Camber Pharmaceuticals Launches Temozolomide Capsules for Brain Cancer Treatment
• Camber Pharmaceuticals has announced the launch of Temozolomide Capsules, USP, an alkylating drug used in the treatment of glioblastoma and anaplastic astrocytoma in adults. • The medication will be available in five different strengths (5mg, 20mg, 100mg, 140mg, 180mg, and 250mg) and in various count options to support different treatment regimens. • Temozolomide is primarily used as a concurrent treatment with radiotherapy for newly diagnosed glioblastoma patients, followed by maintenance therapy, addressing critical needs in brain cancer treatment.
First Generic Eltrombopag Launches, Expanding Access for Thrombocytopenia and Aplastic Anemia Patients
Camber Pharmaceuticals has launched the first AB-rated generic version of eltrombopag (Promacta), offering a more affordable treatment option for patients with thrombocytopenia and aplastic anemia.
Camber Pharmaceuticals Achieves Full DSCSA Compliance Ahead of 2024 Deadline
• Camber Pharmaceuticals has successfully implemented comprehensive DSCSA compliance measures, achieving 100% aggregation from bottle to pallet level for pharmaceutical product tracking. • The company has demonstrated exceptional performance in customer testing with 95-100% success rates, utilizing TraceLink's Verification Routing Services for product authentication since 2022. • In preparation for the November 2024 DSCSA deadline, Camber is increasing inventory levels to support customers whose other suppliers may not achieve full compliance.